- Home
- NB vs STTK Comparison
NB vs STTK Comparison
Compare NB & STTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NB
- STTK
- Stock Information
- Founded
- NB 1987
- STTK 2016
- Country
- NB United States
- STTK United States
- Employees
- NB N/A
- STTK N/A
- Industry
- NB Metal Mining
- STTK Biotechnology: Pharmaceutical Preparations
- Sector
- NB Basic Materials
- STTK Health Care
- Exchange
- NB Nasdaq
- STTK Nasdaq
- Market Cap
- NB 65.9M
- STTK 56.8M
- IPO Year
- NB N/A
- STTK 2020
- Fundamental
- Price
- NB $1.62
- STTK $1.11
- Analyst Decision
- NB Strong Buy
- STTK Hold
- Analyst Count
- NB 2
- STTK 3
- Target Price
- NB $3.63
- STTK $2.00
- AVG Volume (30 Days)
- NB 129.8K
- STTK 172.1K
- Earning Date
- NB 02-11-2025
- STTK 02-27-2025
- Dividend Yield
- NB N/A
- STTK N/A
- EPS Growth
- NB N/A
- STTK N/A
- EPS
- NB N/A
- STTK N/A
- Revenue
- NB N/A
- STTK $6,435,000.00
- Revenue This Year
- NB N/A
- STTK $313.04
- Revenue Next Year
- NB N/A
- STTK N/A
- P/E Ratio
- NB N/A
- STTK N/A
- Revenue Growth
- NB N/A
- STTK 382.75
- 52 Week Low
- NB $1.27
- STTK $0.94
- 52 Week High
- NB $4.00
- STTK $11.76
- Technical
- Relative Strength Index (RSI)
- NB 57.44
- STTK 44.36
- Support Level
- NB $1.49
- STTK $1.13
- Resistance Level
- NB $1.65
- STTK $1.22
- Average True Range (ATR)
- NB 0.12
- STTK 0.11
- MACD
- NB 0.01
- STTK -0.01
- Stochastic Oscillator
- NB 84.62
- STTK 15.15
About NB NioCorp Developments Ltd.
NioCorp Developments Ltd is engaged in exploration and development of mineral deposits in North America, specifically, the Elk Creek Niobium/Scandium/Titanium property.
About STTK Shattuck Labs Inc.
Shattuck Labs Inc is a clinical-stage biotechnology company pioneering the development of dual-sided fusion proteins as an entirely new class of biologic medicine. Its product candidate, SL-172154, has been rationally designed to simultaneously inhibit the CD47/SIRPa checkpoint interaction to restore an anti-tumor immune response and to activate the CD40 costimulatory receptor to bolster an immune response. Its product candidate, SL-279252, which is being developed in collaboration with Takeda Pharmaceuticals, or Takeda, has been rationally designed to simultaneously inhibit the PD-1/PD-L1 interaction and activate the OX40 receptor.